Alcon finalizes deal to acquire Aerie Pharmaceuticals
November 22nd 2022According to the company, the deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.
Read More
Belite Bio completes phase 3 clinical trial plans for LBS-008
November 18th 2022According to the company, LBS-008 is an orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt disease and dry age-related macular degeneration.
Read More
NeoLight rolls out ROP risk management software for pediatric ophthalmology
November 17th 2022According to the company, ROP Check builds upon its pediatric retina screening portfolio, adding digital management (schedule, document, bill, and transfer) for treating patients with retinopathy of prematurity.
Read More
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
October 6th 2022Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).
Read More
Late-breaking: Janssen announces data from 2 gene therapy programs
October 2nd 2022Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
Read More
LUNA: First patient dosed with Ixo-vec in Phase 2 trial for treatment of wet AMD
September 17th 2022LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.
Read More
PHOTON, PULSAR trials: Aflibercept meets primary endpoints in safety, efficacy
September 10th 2022Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
Read More
First patient enrolled in Phase 2 study of D-4517.2 for treatment of wet AMD, DME
September 8th 2022The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.
Read More
First US patient with dry AMD dosed with autologous stem cell therapy
September 8th 2022According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.
Read More
OCS-01 improves macular thickness, visual acuity in patients with DME, according to Phase 2 data
September 7th 2022According to a presentation by Oculis at EURETINA, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.
Read More